Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of Triglyceride-Lowering on Inflammatory Activity in Patients with Hypertriglyceridemia
2021-003168-28Phase 2Completed
- Sponsor
- Academic Medical Center
- Start
- Apr 2022
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in hypertriglyceridemia comparing AKCEA-APOCIII-LRx with Placebo (2 arms). Primary endpoint: Primary. Started Apr 2022; status: completed.
02
Drugs
olezarsen
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on 2021-003168-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003168-28.